What is QNRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for QNRX?

P/E (TTM) is n/a and 52-week range is $3.25 to $23.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s QNRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for QNRX?

The company profile lists net income (TTM) near $-24M, EPS (TTM) near $-12.11 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Quoin Pharmaceuticals Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Kfar Saba, Central(HaMerkaz), IL, 2M shares outstanding, ISIN US74907L4095 when available from company profile and filing metadata.

Free AI scores & summaries library

Quoin Pharmaceuticals Ltd

$QNRX

Health Care · Biotechnology

IR Run Scenarios

$3.90

+0.00%

Free AI scores & summaries library

Quoin Pharmaceuticals Ltd

$QNRX

Health Care · Biotechnology

IR Run Scenarios

$3.90

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The company is headquartered in Kfar Saba, Central(Hamerkaz) and currently employs 4 full-time employees. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

4

Website

quoinpharma.com/

IPO

1989-11-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US74907L4095

Headquarters

Kfar Saba, Central(HaMerkaz), IL

Shares outstanding

2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

62.16%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The company is headquartered in Kfar Saba, Central(Hamerkaz) and currently employs 4 full-time employees. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

4

Website

quoinpharma.com/

IPO

1989-11-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)